---
figid: PMC3693108__BMRI2013-130362.001
figlink: /pmc/articles/PMC3693108/figure/fig1/
number: Figure 1
caption: Therapeutic molecular targets for endometrial cancer. Type I endometrial
  cancer (EC) frequently exhibits altered PI3K/PTEN/AKT/mTOR signal pathway, whereas
  type II EC frequently shows mutations in p53 and HER-2 overexpression. The upregulation
  of EGFR and VEGF, dysregulated microRNAs, and activation of cancer stem cell (CSC)/epithelial-mesenchymal
  transition (EMT) programs are involved in oncogenesis and progression of both cancer
  types. Currently, clinical trials assessing the efficacy of mTOR inhibitor, EGFR/HER2
  inhibitor, and antiangiogenic agent for EC have been conducted and demonstrated
  modest effects.
pmcid: PMC3693108
papertitle: Emerging Therapeutic Biomarkers in Endometrial Cancer.
reftext: Peixin Dong, et al. Biomed Res Int. 2013;2013:130362.
pmc_ranked_result_index: '50798'
pathway_score: 0.9687718
filename: BMRI2013-130362.001.jpg
figtitle: Therapeutic molecular targets for endometrial cancer
year: '2013'
organisms: Homo sapiens
ndex: 5403219d-decb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3693108__BMRI2013-130362.001.html
  '@type': Dataset
  description: Therapeutic molecular targets for endometrial cancer. Type I endometrial
    cancer (EC) frequently exhibits altered PI3K/PTEN/AKT/mTOR signal pathway, whereas
    type II EC frequently shows mutations in p53 and HER-2 overexpression. The upregulation
    of EGFR and VEGF, dysregulated microRNAs, and activation of cancer stem cell (CSC)/epithelial-mesenchymal
    transition (EMT) programs are involved in oncogenesis and progression of both
    cancer types. Currently, clinical trials assessing the efficacy of mTOR inhibitor,
    EGFR/HER2 inhibitor, and antiangiogenic agent for EC have been conducted and demonstrated
    modest effects.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - MAPK3
  - ERBB2
  - AKT1
  - PIK3R3
  - PIK3R5
  - FGFR2
  - VEGFB
  - VEGFA
  - PIK3R6
  - EGFR
  - AKT2
  - MAPKAP1
  - MAPK1
  - KRAS
  - PGF
  - VEGFD
  - NRAS
  - HRAS
  - MLST8
  - FLT1
  - PTEN
  - MAP2K2
  - MAP2K1
  - RICTOR
  - VEGFC
  - MTOR
  - FLT4
  - KDR
  - PIK3CG
  - PIK3CB
  - PIK3CA
  - PIK3CD
  - PIK3R4
  - Cancer
  - Lung cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: EGFR/HER2/FGFR2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: EGFR/HER2/FGFR2
  symbol: FGFR2
  source: hgnc_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: EGFR/HER2/FGFR2
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: PI3K/MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR-2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K/MTOR
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
